News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies Presents Detailed Results of a Clinical Study Showing That VIASKIN® Is Safe and Well-Tolerated by Peanut-Allergic Patients at the European Academy of Allergology and Clinical Immunology Congress



6/18/2012 10:38:06 AM

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the presentation for the first time of the detailed results of its phase Ib clinical study completed earlier this year, representing the first clinical study showing the safety and well-tolerability of Viaskin® in peanut-allergic patients. DBV Technologies also continued to showcase its knowledge in the cellular mechanism implicated during the specific EPIT process and in the Viaskin® Technology with four additional communications presented during the congress.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES